Clinicopathological Characteristics of Prostate Cancer in Tlemcen (Northwestern Algeria)
Keywords:
Prostate Cancer, Epidemiology, Public health, Family history, Screening, AlgeriaAbstract
Background: Prostate cancer is the main cause of cancer death in men in about 48 countries, including several sub-Saharan African, Caribbean, Central and South American countries. Despite the prevalence of prostate cancer, little is known about its etiology. Limited data exist for North Africa, and Algeria in particular, at the crossroads of Sub-Saharan Africa, the Middle East, southern Europe, and the Mediterranean region.
Objective: This study aimed to determine the relationship between a family history of cancer and age at diagnosis, and to assess the effect of a family history of cancer and prostate-specific antigen (PSA) levels on tumor prognosis.
Methods: This cross-sectional study was conducted on the records of 184 patients with prostate cancer confirmed by biopsy, diagnosed between 2011 and 2016 at the Urology Division of Tlemcen’s teaching hospital. The collected data included the age at diagnosis, PSA level on presentation, Gleason score on biopsy, and a family history of cancer. Univariate statistical analyses were performed using ANOVA, independent-samples t-test, and Fisher's exact test in Minitab® 17.
Results: Men who had first-degree female relatives with breast cancer had a younger mean age at diagnosis (67.31 y) than those who did not have the same family history (72.3 y) (p=0.02). Positive first-degree family history for prostate cancer was associated with favorable tumor prognosis (Gleason ≤ 6) at the time of diagnosis (p<0.001). There was also a significant moderate positive correlation (Pearson correlation = 0.35) between PSA level and Gleason score (p<0.001).
Conclusion: Our data suggest an association between positive first-degree family history for breast/prostate cancer and the age of onset. Positive first-degree family history for prostate cancer appears to predict a favorable tumor prognosis. The Gleason score seems to rise with the PSA level. Men with a family history of prostate/breast cancer might start prostate cancer screening earlier than those without the same family history.
This study raises several questions that need to be addressed in future research. Prospective cohort studies would help identify and assess ethnic, genetic, hormonal, and environmental risk factors, and investigate the interactions influencing the genesis of this cancer, thereby guiding public health plans for cancer control and intervention strategies (screening, treatment, and survivor care).
References
Global Cancer Observatory (GLOBOCAN) 2020: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today/home
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660, PMid: 33538338
Bray F, Ferlay J, Soerjomataram I, Siegel R.L, Torre L.A, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394-424. doi: 10.3322/caac.21492, PMid: 30207593
Hamdi Cherif M, Bidoli E, Birri S, et al. Cancer estimation of incidence and survival in Algeria 2014. J Cancer Res Ther. 2015; 3: 100-104. doi: 10.14312/2052-4994.2015-14
Bostwick, David G, Burke H-B, et al. Human prostate cancer risk factors. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2004; 101: 2371-2490. doi: 10.1002/cncr.20408, PMid: 15495199
GANN, Peter H. Risk factors for prostate cancer. Reviews in urology. 2002; 4: S3–S10.
ONS: Office National des Statistiques. Available from: http://www.ons.dz/ (accessed 28/01/18)
Gronberg H, Damber L, Damber JE. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer. 1996; 77: 138-43. doi: 10.1002/(SICI)1097-0142(19960101)77:1<138::AID-CNCR23>3.0.CO;2-5
Cerhan JR, Parker AS, Putnam SD, et al. Family history and prostate cancer risk in a population‐based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev.1999; 8: 53-60.
Thiessen EU. Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer. 1974; 34: 1102-1107. doi: 10.1002/1097-0142(197410)34:4<1102::AID-CNCR2820340421>3.0.CO;2-5
Whittemore AS, Wu AH, Kolonel LN, et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol. 1995; 141: 732-40. doi: 10.1093/oxfordjournals.aje.a117495, PMid: 7535977
Rodriguez C, Calle EE, Tatham LM, et al. Family history of breast cancer as a predictor for fatal prostate cancer. Epidemiology. 1998; 9: 525-9. doi: 10.1097/00001648-199809000-00009, PMid: 9730031
Bratt O, Kristoffersson U, Lundgren R, Olsson H. Familial and hereditary prostate cancer in southern Sweden. A population‐based case‐control study. Eur J Cancer. 1999; 35: 272-7. doi: 10.1016/S0959-8049(98)00358-X
Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer. 2003; 97: 1894-1903. doi: 10.1002/cncr.11262, PMid: 12673715
Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003; 91: 789-94. doi: 10.1046/j.1464-410X.2003.04232.x, PMid: 12780833
Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22: 735-42. doi: 10.1200/JCO.2004.05.055, PMid: 14966099
Gallagher DJ, Gaudet MM, Pal P et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-21. doi: 10.1158/1078-0432.CCR-09-2871, PMid: 20215531, PMCid: PMC3713614
Andrieu N, Clavel F, Auquier A, et al. Association between breast cancer and family malignancies. Eur J Cancer. 1991; 27: 244-8. doi: 10.1016/0277-5379(91)90506-9
Rodriguez C, Calle EE, Miracle-McMahill HL, Tatham LM, Wingo PA, Thun MJ. Family history and risk of fatal prostate cancer. Epidemiology 1997; 8: 653-7. doi: 10.1097/00001648-199711000-00011, PMid: 9345665
Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA. Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 1997; 15: 1478-80. doi: 10.1200/JCO.1997.15.4.1478, PMid: 9193343
Azzouzi AR, Valeri A, Cormier L, Fournier G, Mangin P, Cussenot O. Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. Urology 2003; 61: 1193-7. doi: 10.1016/S0090-4295(03)00033-5
Gronberg H, Damber L, Tavelin B, Damber JE. No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 1998; 82: 564-7. doi: 10.1046/j.1464-410X.1998.00801.x, PMid: 9806189
Hanlon AL, Hanks GE. Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer. Urology 1998; 52: 735-8. doi: 10.1016/S0090-4295(98)00398-7
Valeri A, Azzouzi R, Drelon E, Delannoy A, Mangin P, Fournier G. Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate 2000; 45: 66-71. doi: 10.1002/1097-0045(20000915)45:1<66::AID-PROS8>3.0.CO;2-W
Kotsis SV, Spencer SL, Peyser PA,Montie JE, Cooney KA. Early onset prostate cancer: predictors of clinical grade. J Urol. 2002; 167: 1659-63. doi: 10.1016/S0022-5347(05)65173-7
Rohrmann S, Roberts WW, Walsh PC, Platz EA. Family history of prostate cancer and obesity in relation to high‐grade disease and extraprostatic extension in young men with prostate cancer. Prostate. 2003; 55: 140-146. doi: 10.1002/pros.10211, PMid: 12661039
Ang, M., Borg, M., O’Callaghan, M.E. et al. Survival outcomes in men with a positive family history of prostate cancer: a registry based study. BMC Cancer 2020; 20: 894. doi: 10.1186/s12885-020-07174-9, PMid: 32948129, PMCid: PMC7499864
Whiteland H, Spencer-Harty S, Hywel T, et al. Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer. Experimental and molecular pathology. 2013; 95: 220-6. doi: 10.1016/j.yexmp.2013.07.010, PMid: 23933194
Sanjaya, I.Putu Gde, et al. Correlation between Low Gleason Score and Prostate Specific Antigen Levels with Incidence of Bone Metastases in Prostate Cancer Patients: When to Omit Bone Scans?. Asian Pacific Journal of Cancer Prevention 2013; 14: 4973-6. doi: 10.7314/APJCP.2013.14.9.4973, PMid: 24175761
Okolo, C.A., Akinosun, O.M., Shittu, O.B. et al. Correlation of serum PSA and Gleason score in Nigerian men with prostate cancer. Afr J Urol 2008; 14: 15-22. doi: 10.1007/BF02994508
Helpap B, Egevad L. Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens. Analytical and Quantitative Cytology and Histology. 2008 Jun;30(3):133-8.
Kanthilatha P, Gauri S.A, Ranjini K, Padmaraj H. Diagnostic correlation between serum PSA, gleason score and bone scan results in prostatic cancer patients with bone metastasis. British Biomedical Bulletin 2015; 3: 1-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Knowledge Kingdom Publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
